Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The improvement in survival of the systemic vasculitides with the use of current immunosuppression has heightened awareness of their poor long-term outcome in terms of chronic morbidity and relapse. Assessment of systemic vasculitis is an essential part of its management. Better understanding of the underlying pathophysiology of the antineutrophil cytoplasmic antibody-related vasculitides has resulted in improved assays and may result in more precise serologic assessment of disease. Clinical assessment tools for accurately measuring disease activity and damage have been developed and are reviewed in this article. It is becoming increasingly clear that these clinical tools are practical, effective measures that can assist in the treatment of individual patients and play an important role in clinical trials of systemic vasculitis.

Original publication

DOI

10.1097/00002281-200201000-00005

Type

Journal article

Journal

Current opinion in rheumatology

Publication Date

01/2002

Volume

14

Pages

23 - 28

Addresses

Consultant Rheumatologist and Part Time Senior Lecturer, Rheumatology Department, University of Edinburgh, Edinburgh, United Kingdom. raashid.luqmani@ed.ac.uk

Keywords

Humans, Vasculitis, Immunologic Tests, Prognosis, Severity of Illness Index